Analysis of Clinical Subphenotypes in Methicillin-Resistant Staphylococcus aureus Bacteremia: A Post Hoc Analysis of the MRSA-GEIRAS-SEIMC Study - Scorecard - MDSpire
Advertisement
Analysis of Clinical Subphenotypes in Methicillin-Resistant Staphylococcus aureus Bacteremia: A Post Hoc Analysis of the MRSA-GEIRAS-SEIMC Study
Clinical Scorecard: Evaluation of Clinical Subphenotypes in Methicillin-Resistant Staphylococcus aureus Bacteremia: Insights from a Post Hoc Analysis of the MRSA-GEIRAS-SEIMC Study
Identification of clinical subphenotypes based on demographics, comorbidities, infection source, acquisition type, and organ failure scores to assess mortality risk
Target Population
Adult patients with MRSAB treated in 15 Spanish hospitals from 2019 to 2022
Care Setting
Hospital inpatient settings across multiple centers
Key Highlights
Four distinct clinical subphenotypes of MRSAB were identified with differing 90-day mortality rates: S1 (20.0%), S2 (47.4%), S3 (26.2%), and S4 (35.1%).
Subphenotypes S2 (older age, female sex, high comorbidity, healthcare-related acquisition) and S4 (heart valve prostheses, metastatic foci) had significantly higher mortality risk.
Traditional SAB classifications may not capture important prognostic factors; subphenotyping could improve risk stratification and guide therapy.
Guideline-Based Recommendations
Diagnosis
Confirm MRSAB via positive peripheral blood cultures with methicillin resistance determined phenotypically or genotypically.
Assess clinical variables including age, sex, comorbidities, SOFA score, infection source, and acquisition type for subphenotype classification.
Management
Consider combination antibiotic therapy (≥2 MRSA-active agents for ≥48 hours) especially in high-risk subphenotypes, though clear clinical benefit remains unproven.
Tailor treatment strategies based on subphenotype risk profiles to potentially improve outcomes.
Monitoring & Follow-up
Monitor all-cause mortality at 30 and 90 days post-MRSAB onset.
Evaluate for metastatic foci and treatment-related adverse events during therapy.
Risks
Higher mortality risk associated with older age, female sex, high comorbidity burden, healthcare-related acquisition, presence of heart valve prostheses, and metastatic infection sites.
Traditional uncomplicated vs complicated SAB classifications may underestimate risk in certain patient groups.
Patient & Prescribing Data
Adults with MRSAB episodes treated in hospital settings
Combination therapy was used in a subset of patients; however, no definitive mortality benefit was demonstrated, highlighting the need for risk stratification by subphenotype to guide therapy.
Clinical Best Practices
Use comprehensive clinical and laboratory data to classify MRSAB patients into subphenotypes for prognostic assessment.
Recognize that patients in subphenotypes S2 and S4 have increased 90-day mortality risk and may require closer monitoring and tailored management.
Incorporate subphenotype classification alongside traditional severity scores to improve clinical decision-making.
Exclude patients with early death, polymicrobial bacteremia, or incomplete data when applying subphenotype models to ensure accuracy.
by Sofía De La Villa, Nuria Fernández-Hidalgo, Francesc Escrihuela-Vidal, Rosa Escudero-Sánchez, Itxasne Cabezón, Lucía Boix-Palop, Beatriz Díaz-Pollán, Ane Josune Goikoetxea, María José García-País, Lucía Ramos-Merino, María Teresa Pérez-Rodríguez, Ángela Crespo, Lara del Río, José María Bellón-Cano, Patricia Muñoz, on behalf of, MRSA-GEIRAS-SEIMC study group, Damaris Berbel, Luis Buzón-Martín, David Campany, Alex García-Tellado, Inmaculada Grau, José Manuel Guerra-Laso, Joan Roig-Sanchis, Celia Sánchez-Martínez, Oscar Sanz, Fiorana Silvante, Belén Viñado, Luciana Urbina, Ana V Halperin, Mariona Xercavins
